and one of the most advanced programs in AstraZeneca’s ADC scientific platform. Datopotamab deruxtecan is comprised of a ...

The 13-year veteran is teaming up with AstraZeneca for their Get Body Checked Against Cancer public health campaign.

UBS analyst Matthew Weston maintained a Sell rating on AstraZeneca (AZN – Research Report) today and set a price target of £113.00. The ...

Effectiveness and safety data from Viking’s study, released Sunday at an industry conference, show that an obesity pill could ...

Powerful weight-loss drugs like Wegovy and Zepbound have driven nearly $1 trillion in market-capitalization gains, with most of those gains flowing to Eli Lilly and Novo Nordisk, the dominant players ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

The AstraZeneca PLC ADR AZN inched 0.01% higher to $71.43 Monday, on what proved to be an all-around grim trading session for ...

Cellectis is confident about the continued progress of its ongoing clinical trials in hematological malignancies and is ...

Novo Nordisk reports earnings Wednesday morning, with sales of blockbuster weight-loss drugs Ozempic and Wegovy expected to continue driving the Danish drugmaker's results higher.

Viking Therapeutics' highly anticipated weight-loss pill topped Wall Street's expectations — and a rival pill from Novo ...

AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...